Company: IMCR
Filing Date: 2025-02-26
Form Type: 8-K
Source: 0001140361-25-005988
Chunk: 1

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On February 25, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of the
Company (the “ Board”), the Board appointed William Pao, M. D., Ph. D. to serve as a Class II director of the Company, effective February 25, 2025. Dr. Pao will serve for a term expiring at the Company’s 2026 annual meeting of shareholders, and
until his successor is elected and has been qualified, or until his earlier death, resignation or removal.

William Pao, M. D., Ph. D., age 57, is the co-founder and since May 2024 has served as the Chief Executive Officer of Revelio
Therapeutics, Inc. Prior to Revelio, Dr. Pao served as the Chief Development Officer, Executive Vice President at Pfizer, Inc. from March 2022 to August 2023. He also previously served in various roles at F. Hoffmann-LaRoche AG from May 2014 to
March 2022, including most recently as its Head of Pharma Research & Early Development and as a member of its Enlarged Corporate Executive Committee from April 2018 until March 2022. In addition to his role at Revelio, Dr. Pao has served as
an Adjunct Professor of Pharmacology and Medicine at the Joan & Sanford I. Weill Medical College of Cornell University since May 2024 and as an Adjunct Professor of Medicine at Vanderbilt University Medical Center since 2014. Dr. Pao is also
a member of the board of directors of the American Association for Cancer Research, as well as the boards of directors of Obsidian Therapeutics, Inc. and Alentis Therapeutics, AG. Dr. Pao has a B. A. from Harvard University and an M. D. and Ph. D.
from Yale University.

Dr. Pao will be compensated in accordance with the Company’s non-executive director remuneration policy (the “ Remuneration Policy”)
as described in the Company’s definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 12, 2024, as amended in December 2024. Pursuant to the Remuneration Policy, Dr. Pao